Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10

Andrea Bezjak, Christopher W. Lee, Keyue Ding, Michael Brundage, Timothy Winton, Barbara Graham, Marlo Whitehead, David H. Johnson, Robert B Livingston, Lesley Seymour, Frances A. Shepherd

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Purpose: Adjuvant chemotherapy for early stage non-small-cell lung cancer (NSCLC) is now the standard of care, but there is little information regarding its impact on quality of life (QOL). We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC. Patients and Methods: QOL was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline and at weeks 5 and 9 for those who received chemotherapy and at follow-up months 3, 6, 9, 12, 18, 24, 30 and 36. A 10-point change in QOL scores from baseline was considered clinically significant. Results: Four hundred eighty-two patients were randomly assigned on JBR.10. A total of 173 patients (82% of the expected) in the observation arm and 186 (85% of expected) in the chemotherapy arm completed baseline QOL assessments. The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy. Changes in QOL during chemotherapy were relatively modest; fatigue, nausea, and vomiting worsened, but there was a reduction in pain and no change in global QOL. Patients in the observation arm showed considerable improvements in QOL by 3 months. QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months. Conclusion: The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.

Original languageEnglish (US)
Pages (from-to)5052-5059
Number of pages8
JournalJournal of Clinical Oncology
Volume26
Issue number31
DOIs
StatePublished - Nov 1 2008
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Quality of Life
Drug Therapy
Observation
Fatigue
Pain
Thoracotomy
Standard of Care
Checklist
Hearing Loss
Nausea
Cisplatin
Vomiting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer : Results from a randomized trial, JBR.10. / Bezjak, Andrea; Lee, Christopher W.; Ding, Keyue; Brundage, Michael; Winton, Timothy; Graham, Barbara; Whitehead, Marlo; Johnson, David H.; Livingston, Robert B; Seymour, Lesley; Shepherd, Frances A.

In: Journal of Clinical Oncology, Vol. 26, No. 31, 01.11.2008, p. 5052-5059.

Research output: Contribution to journalArticle

Bezjak, A, Lee, CW, Ding, K, Brundage, M, Winton, T, Graham, B, Whitehead, M, Johnson, DH, Livingston, RB, Seymour, L & Shepherd, FA 2008, 'Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10', Journal of Clinical Oncology, vol. 26, no. 31, pp. 5052-5059. https://doi.org/10.1200/JCO.2007.12.6094
Bezjak, Andrea ; Lee, Christopher W. ; Ding, Keyue ; Brundage, Michael ; Winton, Timothy ; Graham, Barbara ; Whitehead, Marlo ; Johnson, David H. ; Livingston, Robert B ; Seymour, Lesley ; Shepherd, Frances A. / Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer : Results from a randomized trial, JBR.10. In: Journal of Clinical Oncology. 2008 ; Vol. 26, No. 31. pp. 5052-5059.
@article{057134bef43d4c46bc6cff54618e60cf,
title = "Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Results from a randomized trial, JBR.10",
abstract = "Purpose: Adjuvant chemotherapy for early stage non-small-cell lung cancer (NSCLC) is now the standard of care, but there is little information regarding its impact on quality of life (QOL). We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC. Patients and Methods: QOL was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline and at weeks 5 and 9 for those who received chemotherapy and at follow-up months 3, 6, 9, 12, 18, 24, 30 and 36. A 10-point change in QOL scores from baseline was considered clinically significant. Results: Four hundred eighty-two patients were randomly assigned on JBR.10. A total of 173 patients (82{\%} of the expected) in the observation arm and 186 (85{\%} of expected) in the chemotherapy arm completed baseline QOL assessments. The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy. Changes in QOL during chemotherapy were relatively modest; fatigue, nausea, and vomiting worsened, but there was a reduction in pain and no change in global QOL. Patients in the observation arm showed considerable improvements in QOL by 3 months. QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months. Conclusion: The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.",
author = "Andrea Bezjak and Lee, {Christopher W.} and Keyue Ding and Michael Brundage and Timothy Winton and Barbara Graham and Marlo Whitehead and Johnson, {David H.} and Livingston, {Robert B} and Lesley Seymour and Shepherd, {Frances A.}",
year = "2008",
month = "11",
day = "1",
doi = "10.1200/JCO.2007.12.6094",
language = "English (US)",
volume = "26",
pages = "5052--5059",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "31",

}

TY - JOUR

T1 - Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer

T2 - Results from a randomized trial, JBR.10

AU - Bezjak, Andrea

AU - Lee, Christopher W.

AU - Ding, Keyue

AU - Brundage, Michael

AU - Winton, Timothy

AU - Graham, Barbara

AU - Whitehead, Marlo

AU - Johnson, David H.

AU - Livingston, Robert B

AU - Seymour, Lesley

AU - Shepherd, Frances A.

PY - 2008/11/1

Y1 - 2008/11/1

N2 - Purpose: Adjuvant chemotherapy for early stage non-small-cell lung cancer (NSCLC) is now the standard of care, but there is little information regarding its impact on quality of life (QOL). We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC. Patients and Methods: QOL was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline and at weeks 5 and 9 for those who received chemotherapy and at follow-up months 3, 6, 9, 12, 18, 24, 30 and 36. A 10-point change in QOL scores from baseline was considered clinically significant. Results: Four hundred eighty-two patients were randomly assigned on JBR.10. A total of 173 patients (82% of the expected) in the observation arm and 186 (85% of expected) in the chemotherapy arm completed baseline QOL assessments. The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy. Changes in QOL during chemotherapy were relatively modest; fatigue, nausea, and vomiting worsened, but there was a reduction in pain and no change in global QOL. Patients in the observation arm showed considerable improvements in QOL by 3 months. QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months. Conclusion: The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.

AB - Purpose: Adjuvant chemotherapy for early stage non-small-cell lung cancer (NSCLC) is now the standard of care, but there is little information regarding its impact on quality of life (QOL). We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC. Patients and Methods: QOL was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline and at weeks 5 and 9 for those who received chemotherapy and at follow-up months 3, 6, 9, 12, 18, 24, 30 and 36. A 10-point change in QOL scores from baseline was considered clinically significant. Results: Four hundred eighty-two patients were randomly assigned on JBR.10. A total of 173 patients (82% of the expected) in the observation arm and 186 (85% of expected) in the chemotherapy arm completed baseline QOL assessments. The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy. Changes in QOL during chemotherapy were relatively modest; fatigue, nausea, and vomiting worsened, but there was a reduction in pain and no change in global QOL. Patients in the observation arm showed considerable improvements in QOL by 3 months. QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months. Conclusion: The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.

UR - http://www.scopus.com/inward/record.url?scp=55649089263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649089263&partnerID=8YFLogxK

U2 - 10.1200/JCO.2007.12.6094

DO - 10.1200/JCO.2007.12.6094

M3 - Article

C2 - 18809617

AN - SCOPUS:55649089263

VL - 26

SP - 5052

EP - 5059

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 31

ER -